"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04094727","Malaria High-Risk Populations in Namibia",,"Enrolling by invitation","No Results Available","Malaria","Drug: Presumptive treatment with Artemether-lumefantrine (AL)|Other: Enhanced vector control","Effective coverage of AL (presumptive treatment)|Effective coverage of IRS|Effective coverage of LLIN|Prevalence of infection measured by polymerase chain reaction (PCR)|Odds of symptomatic malaria associated with receiving each intervention|Total confirmed outpatient (OPD) malaria case incidence by health facility, stratified by HRP status|Malaria seroprevalence in HRPs|Test positivity rates from RACD|Entomological Indicators|Intervention acceptability as evaluated by participation rate|Intervention acceptability as evaluated by qualitative assessment|Cost effectiveness|Adherence to presumptive treatment intervention as evaluated by pill count|Self-reported compliance to LLIN and topical repellents.|HRP population size|HRP movement patterns","University of California, San Francisco|University of Namibia|Ministry of Health and Social Services, Namibia|University of Texas Southwestern Medical Center|University of Notre Dame|London School of Hygiene and Tropical Medicine","All","6 Months and older   (Child, Adult, Older Adult)","Phase 4","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Malaria HRP in Namibia","October 31, 2019","May 31, 2020","May 31, 2020","September 19, 2019",,"November 13, 2019","University of Namibia, Multidisciplinary Research Centre, Windhoek, Namibia",,"https://ClinicalTrials.gov/show/NCT04094727"
2,"NCT03334747","Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.",,"Recruiting","No Results Available","Malaria","Drug: KAE609|Drug: Coartem","At least 2 CTCAE grades increase from baseline in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the 4 week study period|Polymerase Chain Reaction (PCR) corrected Clinical and Parasitological Cure|Recrudescence|Parasite Clearance Time|Proportion of patients with parasitaemia|Maximum Peak Observed Concentration (Cmax)|Area under the curve (AUC)|Time after administration of a drug when the maximum plasma concentrations is reached (Tmax)|Half-life (T½)|Uncorrected Adequate Clinical and Parasitological Response|Fever Clearance Time","Novartis Pharmaceuticals|Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","210","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CKAE609A2202","November 16, 2017","November 25, 2019","April 30, 2020","November 7, 2017",,"January 27, 2020","Novartis Investigative Site, Lambarene, Gabon|Novartis Investigative Site, Kintampo, Ghana|Novartis Investigative Site, Navrango, Ghana|Novartis Investigative Site, Bamako, Mali|Novartis Investigative Site, Sotuba, Mali|Novartis Investigative Site, Kigali, Rwanda|Novartis Investigative Site, Bushenyi, Uganda|Novartis Investigative Site, Kampala, Uganda|Novartis Investigative Site, Tororo, Uganda",,"https://ClinicalTrials.gov/show/NCT03334747"
3,"NCT02694874","Rosiglitazone Adjunctive Therapy for Severe Malaria in Children","ROSI","Recruiting","No Results Available","Malaria","Drug: Rosiglitazone|Drug: Placebo","Change in serum Ang-2 levels in the first 96 hours of hospital admission.|Time to clinical recovery|Time to parasitological recovery|Mortality|Blood lactate levels, assessed at admission, every 12h for 24 hours then daily for Blood lactate levels|Change in levels of biomarkers of host response|Blood glucose levels|Cardiac effects|Biochemical and hematological parameters|AE/SAE|Neurocognitive outcomes","Centro de Investigacao em Saude de Manhica|University Health Network, Toronto|Barcelona Institute for Global Health","All","12 Months to 12 Years   (Child)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ROSI_v03_22072015","February 2016","June 2020","December 2020","March 1, 2016",,"October 1, 2019","Centro de Investigação em Saude da Manhiça, Manhiça, Maputo, Mozambique",,"https://ClinicalTrials.gov/show/NCT02694874"
4,"NCT02149550","Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains",,"Completed","No Results Available","Malaria","Other: NF135 n=5|Other: NF135 n=2|Other: NF135 n=1|Other: NF166 n=5|Other: NF166 n=2|Other: NF166 n=1","Proportion of subjects in each group who develop patent parasitaemia as assessed by QRT-PCR|Time to patent parasitaemia in each group as assessed by QRT-PCR|Magnitude of first peak of parasitaemia in each group as assessed by QRT-PCR|Frequency of malaria-related symptoms and signs in each group","Radboud University|Havenziekenhuis","All","18 Years to 35 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","BMGF2a","August 2014","October 2014","November 2014","May 29, 2014",,"November 24, 2014","UMC St Radboud, Nijmegen, Netherlands|Havenziekenhuis, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02149550"
5,"NCT04102592","Getting Malaria ""Off the Back"" of Women and Children in Western Uganda",,"Recruiting","No Results Available","Malaria","Other: Permethrin-treated Lesu (baby wrap)|Other: Untreated Lesu (baby wrap)","Reported change in frequency of use of lesu|Incidence of symptomatic malaria episodes among children|Incidence of P. falciparum malaria parasitemia among children|Change in mosquito salivary antigen response among children|Change in mosquito salivary antigen response among mothers|Changes in hemoglobin levels among children|Changes in hemoglobin levels among mothers","University of North Carolina, Chapel Hill|Conservation, Food, and Health Foundation","Female","18 Years to 50 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18-1819|IGHID 11829","October 28, 2019","December 2020","December 2020","September 25, 2019",,"November 14, 2019","Bugoye Level III Health Centre, Bugoye, Kasese, Uganda",,"https://ClinicalTrials.gov/show/NCT04102592"
6,"NCT04072302","Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model",,"Completed","No Results Available","Malaria","Drug: KAF156|Drug: Placebo","Number of subjects with parasitemia after single dose oral administration of KAF156 either prior to, or following, exposure to P. falciparum sporozoite-infected mosquitoes|Relationship between pharmacokinetics (i.e., Maximum Plasma Concentration [Cmax], Area Under Curve [AUC]) of KAF156 and number of subjects with parasitemia, after oral administration of single descending doses of KAF156 in healthy subjects with CHMI|Number of subjects with adverse events, serious adverse events, and death|Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)|Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Pharmacokinetics of KAF156: Area under teh plasma concentration-time curve from time zero to time 24 h (AUC0-24)|Pharmacokinetics of KAF156: Terminal elimination half life (T1/2)|Pharmacokinetics of KAF156: Apparent systemic clearance from plasma following oral administration (CL/F)|Pharmacokinetics of KAF156: Apparent volume of distribution during the terminal phase following oral administration (Vz/F)|Pharmacokinetics of KAF156: Observed maximum plasma concentration (Cmax)|Pharmacokinetics of KAF156: Time to reach the maximum concentration (Tmax)|Parasite growth Kinetics by qRT-PCR","Novartis Pharmaceuticals|Novartis","Male","18 Years to 40 Years   (Adult)","Phase 1","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CKAF156X2202","September 15, 2014","November 29, 2017","November 29, 2017","August 28, 2019",,"August 28, 2019","Novartis Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04072302"
7,"NCT01939886","Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","TRANSACT2","Completed","No Results Available","Malaria","Drug: Mefloquine - Artesunate|Drug: Artemether-lumefantrine combination","the number of participants with clinical and parasitological treatment failure after treatment artemether-lumefantrine (AL) and mefloquine-artesunate MQ-AS|the number of individuals with gametocytes after treatment with AL or MQ-AS","London School of Hygiene and Tropical Medicine|Kilimanjaro Christian Medical Centre, Tanzania|Radboud University|European Union","All","6 Months to 10 Years   (Child)","Phase 3","219","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","TRANSACT 2","April 2013","November 2013","November 2013","September 11, 2013",,"November 28, 2013","St. Jude's Clinic, ICIPE Thomas Odhiambo Campus, Mbita, Nyanza, Kenya",,"https://ClinicalTrials.gov/show/NCT01939886"
8,"NCT03594084","Malaria in Strasbourg University Hospital","ACMUS","Recruiting","No Results Available","Malaria",,"Study of clinical characteristics of imported malaria in people originated from endemic areas hospitalized at Strasbourg University Hospital from 2017 to 2018.","University Hospital, Strasbourg, France","All","Child, Adult, Older Adult",,"70","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","7084","August 1, 2018","August 2019","August 2019","July 20, 2018",,"September 17, 2018","Service de Maladies Infectieuses et Tropicales, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03594084"
9,"NCT02153996","Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States",,"Terminated","No Results Available","Malaria",,"Estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure.|Compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to age and sex matched individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"3","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140121|14-I-0121","May 15, 2014","March 15, 2016","March 15, 2016","June 3, 2014",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02153996"
10,"NCT02315690","Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland","fMDA","Completed","No Results Available","Malaria","Drug: dihydroartemisinin-piperaquine (DHAp)|Procedure: reactive case detection","Incidence of malaria cases|Seroprevalence|Prevalence|Coverage|Adherence|Safety related to DHAp|Acceptability|Cost","University of California, San Francisco|Ministry of Health, Swaziland|Clinton Health Access Initiative, Nigeria|University of Texas","All","Child, Adult, Older Adult","Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Swaziland fMDA","September 2015","July 2017","July 2017","December 12, 2014",,"October 30, 2017","Swaziland Ministry of Health, Mbabane, Swaziland",,"https://ClinicalTrials.gov/show/NCT02315690"
11,"NCT01624337","Malaria Prevention Cambodia","MPC","Terminated","No Results Available","Malaria","Drug: DHA-piperaquine|Drug: placebo","Protective efficacy|Cardiac safety of piperaquine as determined by QT interval prolongation","Armed Forces Research Institute of Medical Sciences, Thailand|National Centre for Parasitology, Entomology and Malaria Control, Cambodia|Royal Cambodian Armed Forces|United States Army Medical Materiel Development Activity","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","231","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","WRAIR # 1849|A-17057","May 2012","August 2014","June 2015","June 20, 2012",,"July 12, 2016","Anlong Veng Referral Hospital, Anlong Veng, Oddar Meancheay, Cambodia",,"https://ClinicalTrials.gov/show/NCT01624337"
12,"NCT02174978","Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults",,"Completed","No Results Available","Malaria","Biological: FMP012 with AS01B adjuvant system|Other: P falciparum Controlled Human Malaria Infection (CHMI)","Number of solicited adverse events (AE)|Number of unsolicited AEs|Occurrence of serious adverse events (SAE) at any time during the study period (enrollment to final follow-up visit)|Anti-FMP012 antibody titers in serum|Time to parasitemia by blood smear after the P falciparum challenge","U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID)|Military Infectious Diseases Research Program (MIDRP)|GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 1","39","U.S. Fed|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","S-14-02","August 2014","June 2015","October 2015","June 26, 2014",,"October 13, 2017","Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02174978"
13,"NCT01231880","School Based Malaria Control in Ugandan Schoolchildren","SBMC","Completed","No Results Available","Malaria","Drug: Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Drug: Monthly IPT using DP|Drug: Placebo given every month","Risk of Clinical Malaria|Cognitive function tests|Risk of parasitemia|Risk of hospital admissions|Risk of adverse events|School performance|Prevalence of anemia","Makerere University|Bill and Melinda Gates Foundation","All","6 Years to 14 Years   (Child)","Phase 3","740","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MCDC-SBMC","February 2011","September 2012","September 2012","November 1, 2010",,"May 23, 2013","Mulanda Sub-district, Tororo, Uganda",,"https://ClinicalTrials.gov/show/NCT01231880"
14,"NCT01443130","Chloroquine for Malaria in Pregnancy",,"Completed","Has Results","Malaria","Drug: Chloroquine|Drug: Sulfadoxine-pyrimethamine","Incidence of Placental Malaria Infection Based on Histology|Incidence of Placental Malaria by Placental Impression Smear|Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter)|Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl)|Incidence of Stillbirth|Incidence of Miscarriage|Incidence of Preterm Delivery|Infant Mortality Rate to 14 Weeks of Age|Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams)|Incidence of Intrauterine Growth Restriction (IUGR)|Incidence of Active Placental Malaria Infection|Incidence of Malaria Infection, All Species.|Incidence of Clinical Malaria, All Species|Incidence of Infection in the Fetal Circulation","National Institute of Allergy and Infectious Diseases (NIAID)","Female","up to 99 Years   (Child, Adult, Older Adult)","Phase 3","900","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","09-0112|4R01AI104702-04","February 2012","October 2014","January 2015","September 29, 2011","October 29, 2015","December 28, 2016","Blantyre Malaria Project - Queen Elizabeth Central Hospital, Blantryre, Blantyre, Malawi",,"https://ClinicalTrials.gov/show/NCT01443130"
15,"NCT03387631","Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania","TES2016","Completed","No Results Available","Uncomplicated Malaria","Drug: Artemether-Lumefantrine","Cure rates as per WHO protocol","National Institute for Medical Research, Tanzania","All","6 Months to 10 Years   (Child)",,"344","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NIMRTanzania","April 2016","September 2016","September 2016","January 2, 2018",,"January 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03387631"
16,"NCT02394522","Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)","SR-M-ZM","Withdrawn","No Results Available","Malaria","Device: Spatial Repellent product with active ingredient (SHIELD)|Device: Active Ingredient|Device: Spatial Repellent product without active ingredient (SHIELD)","Malaria Incidence","University of Notre Dame|Ministry of Health, Zambia|Macha Research Trust, Zambia|Johns Hopkins University","All","6 Months to 59 Months   (Child)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SR-M-Zm","March 2016","April 2016","April 2016","March 20, 2015",,"October 6, 2016","Macha Research Trust, Macha, Choma, Zambia",,"https://ClinicalTrials.gov/show/NCT02394522"
17,"NCT02294201","Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya","SR-M-KEN","Withdrawn","No Results Available","Malaria","Device: Spatial Repellent product with active ingredient|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD)","Malaria Incidence","University of Notre Dame|Centers for Disease Control and Prevention|Kenya Medical Research Institute","All","6 Months to 59 Months   (Child)","Not Applicable","0","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SR-M-KEN","June 2016","July 2016","July 2016","November 19, 2014",,"October 6, 2016","Kemri-Crc, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT02294201"
18,"NCT02294188","Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia","SR-M-IDR","Completed","No Results Available","Malaria","Device: Spatial Repellent product with active ingredient (SHIELD)|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD)","Malaria Incidence","University of Notre Dame|Ministry of Health, Indonesia","All","6 Months to 59 Months   (Child)","Not Applicable","1519","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SR-M-IDR","May 2015","April 15, 2018","April 15, 2018","November 19, 2014",,"May 3, 2018","Eijkman Institute for Molecular Biology, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02294188"
19,"NCT02294214","Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania","SR-M-Tz","Withdrawn","No Results Available","Malaria","Device: Spatial Repellent product with active ingredient|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD)","Malaria Incidence","University of Notre Dame|Ifakara Health Institute","All","6 Months to 59 Months   (Child)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SR-M-TZ","February 2016","April 2016","April 2016","November 19, 2014",,"October 6, 2016","Ifakara Health Institute, Bagamoyo, Tanzania",,"https://ClinicalTrials.gov/show/NCT02294214"
20,"NCT01627951","Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection","TIP3","Completed","No Results Available","Malaria","Other: NF54|Other: NF135|Other: NF166","Difference in kinetics of infection between groups infected with NF54, NF133 and NF166, as defined by a mathematical model that takes into account multiple measurements of parasitaemia|Difference in time till thick smear positivity between groups infected with NF54, NF135 and NF166|Difference in duration or peak height of parasitaemia between groups infected with NF54, NF135 and NF166|Difference in frequency of malaria-related symptoms and signs between groups infected with NF54, NF135 and NF166|Difference in induced immunological responses between groups infection with NF54, NF135 and NF166","Radboud University|Havenziekenhuis","All","18 Years to 35 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","TIP3","August 2012","October 2012","November 2012","June 26, 2012",,"November 27, 2012","UMC St Radboud, Nijmegen, Netherlands|Havenziekenhuis, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01627951"
21,"NCT04176029","Lung Ultrasound in Children With Severe Malaria","LUSiSM","Not yet recruiting","No Results Available","Severe Malaria","Device: lung ultrasound","Proportion of children diagnoses|Proportion of children that fulfill the criteria for a new pulmonary diagnosis >6 hours from admission.|Median lung ultrasound score|Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema.|Hospital mortality and 30 days mortality","University of Oxford|Mahidol Oxford Tropical Medicine Research Unit|University of Kinshasa","All","1 Year to 14 Years   (Child)",,"171","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAL19008","December 1, 2019","August 1, 2020","November 1, 2020","November 25, 2019",,"November 25, 2019","The Maluku District Hospital, Kinshasa, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT04176029"
22,"NCT03341754","Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults",,"Recruiting","No Results Available","Malaria","Biological: D/ChAd63-CA|Biological: D/ChAd63-CAT|Other: Infectivity Control (IC) Group","Occurrence of Serious Adverse Events|Occurrence of Abnormal Physical Symptoms (Clinical Abnormalities)|Occurrence of Abnormal Laboratory Values|Occurrence of Any Serious Adverse Events Throughout the Study Period|Vaccine Efficacy Determined by Time to Development of Parasitemia|Measurement of Antibody Titers Against Sporozoite and Erythrocyte Stage Parasites|Measure of correlation between pre-immunization HuAd5 neutralizing antibody titers and the protective efficacy against CHMI and humoral and cellular immune responses of the 2 prime-boost regimens|Comparison of Immunogenicity of the 2 Vaccine Regimens","U.S. Army Medical Research and Development Command|University of Oxford|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID)|Naval Medical Research Center","All","18 Years to 50 Years   (Adult)","Phase 1","52","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","S-14-07|NMRC.2016.0006|NavOx","September 15, 2018","December 30, 2019","October 2020","November 14, 2017",,"October 26, 2018","NMRC Clinical Trials Center, Bethesda, Maryland, United States|WRAIR, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03341754"
23,"NCT01190202","Epidemiology Study of Malaria Transmission Intensity in Africa",,"Completed","No Results Available","Malaria","Procedure: Blood sampling|Procedure: Assessment of body temperature","Occurrence of Plasmodium falciparum parasitemia during the first year|Occurrence of P. falciparum parasitemia during the second year|Occurrence of P. falciparum parasitemia during the third year|Occurrence of P. falciparum parasitemia during the fourth year|Occurrence of P. falciparum parasitemia|Occurrence of anemia|Occurrence of anti-malarial therapy|Occurrence of fever|Occurrence of each risk factor|Occurrence of malaria prevention measures|Occurrence of other Plasmodium parasitemia","GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)","All","6 Months and older   (Child, Adult, Older Adult)",,"13380","Industry|Other","Observational","Time Perspective: Cross-Sectional","114001","March 2011","December 2013","December 2013","August 27, 2010",,"September 30, 2015","GSK Investigational Site, Ouagadougou 01, Burkina Faso|GSK Investigational Site, Lambaréné, Gabon|GSK Investigational Site, Kintampo, Ghana|GSK Investigational Site, Kumasi, Ghana|GSK Investigational Site, Kisumu, Kenya|GSK Investigational Site, Lilongwe, Malawi|GSK Investigational Site, Dar-es-Salaam, Tanzania|GSK Investigational Site, Korogwe, Tanga, Tanzania",,"https://ClinicalTrials.gov/show/NCT01190202"
24,"NCT02793622","Prevention of Malaria in HIV-uninfected Pregnant Women and Infants","PROMOTE-BC3","Active, not recruiting","No Results Available","Malaria","Drug: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Drug: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy","Proportion of women who deliver with a composite adverse birth outcome|Incidence of malaria in infants|Comparison of estimates of gestational age at birth using two methods|Prevalence of placental malaria by histopathology|Prevalence of placental parasitemia|Prevalence of maternal malaria|Incidence of adverse events in pregnant women|Prevalence of anemia in pregnant women|Prevalence of anemia in infants|Prevalence of asymptomatic parasitemia in pregnant women|Prevalence of asymptomatic parasitemia in infants|Incidence of complicated malaria in infants|Incidence of hospital admissions in infants|Infant mortality rate","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Bill and Melinda Gates Foundation","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","782","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROMOTE-BC3","September 2016","June 2019","June 2019","June 8, 2016",,"July 11, 2018","IDRC - Tororo Research Clinic, Tororo, Uganda",,"https://ClinicalTrials.gov/show/NCT02793622"
25,"NCT02658253","Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults","PRIMALVAC","Completed","No Results Available","Malaria","Biological: PRIMVAC|Biological: GLA-SE|Biological: Alhydrogel|Biological: Placebo","Proportion of volunteers with treatment-related adverse events as assessed by FDA scale and the INYVAX EC FP7 Brighton Collaboration Foundation|Proportion of volunteer with at least one Serious Adverse Event Following Immunization (SAEFI) for the entire duration of the study|Proportion of volunteer with at least one of Adverse Event Following Immunization (AEFI) measured until 1 month post-dose 3|Proportion of volunteer with at least one Adverse Event Following Immunization (AEFI) measured between M3 and the end of the study (only phase Ia)|Variation in humoral immune response to the vaccine antigen assessed by ELISA|Cellular immune responses to the vaccine antigen by Elispot|Cellular immune responses to the vaccine antigen by FACS","Institut National de la Santé Et de la Recherche Médicale, France|EVI Industries, Inc.|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|National Center for Research and Training on Malaria|EUCLID","Female","18 Years to 35 Years   (Adult)","Phase 1","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","C14-60|2015-002246-31","January 2016","September 19, 2018","February 21, 2019","January 18, 2016",,"November 29, 2019","CNRFP, Ouagadougou, Burkina Faso|CIC 1417, Paris, France",,"https://ClinicalTrials.gov/show/NCT02658253"
26,"NCT01464138","Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children",,"Completed","No Results Available","Malaria","Drug: Fosmidomycin and Clindamycin co-administration","Day 28 cure rate >95%|Day 7 cure rate of 100%|Parasite Clearance Time|Fever Clearance Time","Jomaa Pharma GmbH|Fundacio Clinic|Hospital Clinic of Barcelona","All","6 Months to 3 Years   (Child)","Phase 2","52","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JP012","September 2010","September 2011","September 2011","November 3, 2011",,"November 3, 2011","Centro de Investigacao em Saude da Manhica, Maputo, Mozambique",,"https://ClinicalTrials.gov/show/NCT01464138"
27,"NCT02298140","Providers' Compliance to Malaria Treatment","(PCMT)","Unknown status","No Results Available","Malaria","Other: SMS reminders","Provider Compliance|Number of fever patients who received diagnostic test|Number of confirmed malaria patients treated with recommended antimalaria|Number of malaria patients who received correct dose of ACT|Number of patients with a negative malaria test who did not receive antimalaria|Number of afebrile patients who are tested for malaria|Number of patients who received counselling messages|Number of patients who completed antimalaria doses as instructed","Ifakara Health Institute|Swiss Tropical & Public Health Institute|KEMRI-Wellcome Trust Collaborative Research Program","All","Child, Adult, Older Adult","Not Applicable","712","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","3245","November 2014","December 2015","December 2015","November 21, 2014",,"August 3, 2015","Ifakara Health Institute, Rufiji, Pwani, Tanzania",,"https://ClinicalTrials.gov/show/NCT02298140"
28,"NCT01805232","Intravenous Artesunate and Malaria","IVAS","Unknown status","No Results Available","Malaria","Drug: artesunate|Drug: Quinine","clearance of the parasite and fever","University of Khartoum|University of Kassala, Sudan|Kassala|Sudan","All","1 Year to 80 Years   (Child, Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","artesunate and malaria","March 2013","May 2013","July 2013","March 6, 2013",,"March 6, 2013","Kassala, Kassala, Sudan",,"https://ClinicalTrials.gov/show/NCT01805232"
29,"NCT03967054","Repeat Ivermectin Mass Drug Administrations for MALaria Control II","RIMDAMAL II","Recruiting","No Results Available","Malaria","Drug: Ivermectin|Drug: Placebo oral tablet","Malaria incidence|Adverse Events|Blood fed mosquito mortality|Entomological inoculation rate|Human antibody responses to an Anopheles salivary gland peptide|Plasmodium prevalence|Plasmodium parasitemia|Plasmodium multiplicity of infection|Plasmodium molecular force of infection","Brian Foy|Yale University|Institut de Recherche en Sciences de la Sante|Radboud University|PATH|Colorado State University","All","Child, Adult, Older Adult","Phase 3","4700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","18-1803H","July 13, 2019","December 2020","July 2023","May 30, 2019",,"August 28, 2019","Institut de Recherche en Sciences de la Sante, Diebougou, Sud-Ouest, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT03967054"
30,"NCT01323972","Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children",,"Completed","Has Results","Malaria","Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)","Anti-Circumsporozoite (Anti-CS) Antibody Titers|Anti-hepatitis B (Anti-HB) Antibody Concentrations|Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events|Number of Subjects With Serious Adverse Events","GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)","All","5 Months to 17 Months   (Child)","Phase 3","327","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","113398","May 16, 2011","November 22, 2011","May 4, 2012","March 28, 2011","August 7, 2017","August 17, 2018","GSK Investigational Site, Enugu, Nigeria|GSK Investigational Site, Jos, Nigeria",,"https://ClinicalTrials.gov/show/NCT01323972"
31,"NCT03824236","A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults",,"Completed","No Results Available","Malaria","Biological: RTS,S/AS01E (SB257049)","Number of subjects reporting P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge (in all study groups versus infectivity controls)|Time-to-onset of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge in all study groups|Anti-Circumsporozoite (Anti-CS) protein of P. falciparum repeat region antibody concentrations in the booster vaccination groups|Anti-hepatitis B antigen (Anti-HBs) Igtot antibody concentrations in the booster vaccination groups|Number of subjects with solicited local Adverse Events (AEs) in the booster vaccination groups|Number of subjects with solicited general AEs in the booster vaccination groups|Number of subjects with unsolicited AEs following vaccination in the booster vaccination groups|Number of subjects with AEs after challenge in all study groups|Number of subjects with AEs of specific interest in all study groups|Number of subjects with SAEs (all, fatal, related to investigational vaccine) in all study groups|Number of subjects with abnormal laboratory values in the booster vaccination groups|Number of subjects with abnormal laboratory values in the infectivity control subjects","GlaxoSmithKline|PATH","All","18 Years to 55 Years   (Adult)","Phase 2","61","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","209003|17337","February 5, 2019","April 30, 2019","September 26, 2019","January 31, 2019",,"October 4, 2019","GSK Investigational Site, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03824236"
32,"NCT03035305","Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali",,"Completed","No Results Available","Malaria","Dietary Supplement: Lipid-based Nutrient Supplement (LNS)|Drug: Seasonal malaria chemoprevention","Confirmed malaria case|Fever case|Global acute malnutrition case|Moderate acute malnutrition case|Severe acute malnutrition case|Medical referral case","Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale, France|Alliance médicale contre le paludisme, Mali|Programme national de lutte contre le paludisme, Mali|United States Agency for International Development (USAID)|European commission for humanitarian office|Ministry of health, Mali","All","6 Months to 59 Months   (Child)","Not Applicable","36717","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SMC LNS Mali","August 2016","November 2016","November 2016","January 30, 2017",,"January 30, 2017","Amcp/Alima, Kolokani Circle, Koulikoro region, Mali",,"https://ClinicalTrials.gov/show/NCT03035305"
33,"NCT01753323","Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",,"Completed","Has Results","Malaria","Drug: KAF156","Time to Parasite Clearance|28-day Cure Rate - Part 2|Area Under the Curve (AUC)0-24h - Part 1|Maximum Concentration (Cmax) - Part 1|Time to Maximum Concentration (Tmax) - Part 1|Area Under the Curve (AUC)Last - Part 1|Area Under the Curve (AUC)Inf - Part 1|Half-life (T1/2) - Part 1|Clearance (CL/F ) - Part 1|Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1|Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1|AUC0-24h - Part 2|AUC0-48h - Part 2|AUClast - Part 2|AUCinf - Part 2|Cmax - Part 2|Tmax - Part 2|T1/2 - Part 2|CL/F - Part 2|Vz/F - Part 2","Novartis Pharmaceuticals|Novartis","All","20 Years to 60 Years   (Adult)","Phase 2","43","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CKAF156X2201","March 2013","August 2014","August 2014","December 20, 2012","August 19, 2015","June 7, 2018","Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Srisaket, Thailand|Novartis Investigative Site, Tak, Thailand|Novartis Investigative Site, Tak, Thailand|Novartis Investigative Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT01753323"
34,"NCT04020653","A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria",,"Not yet recruiting","No Results Available","Malaria","Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|Drug: Sodium ferrous citrate (SFC) 472 mg QD|Drug: Artemisinin-based combination (ACT)|Drug: Placebo|Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|Drug: Sodium ferrous citrate (SFC) 236 mg BID","Number of patients with adverse events|Cure rate on Day 28|Parasite Clearance Time|Fever Reduction Time|Gametocyte Clearance Time|Change in inflammatory parameter: C-reactive protein|Change in inflammatory parameter: interleukin-6|Change in inflammatory parameter: tumor necrosis factor (TNF)-alpha|Change in iron metabolism: Serum iron|Change in iron metabolism: Hepcidin|Change in iron metabolism: total iron binding capacity (TIBC)|Change in iron metabolism: unsaturated iron binding capacity (UIBC)","Neopharma Japan Co., Ltd.|Parexel","All","18 Years to 60 Years   (Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NPJ005-MAL-0122","September 6, 2019","May 31, 2020","September 30, 2020","July 16, 2019",,"July 16, 2019",,,"https://ClinicalTrials.gov/show/NCT04020653"
35,"NCT03689036","Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimination",,"Recruiting","No Results Available","Malaria",,"Risk factors for residual malaria infection and disease|Genetic characterization of locally circulating malaria parasites over space and time|Estimating the impact of interventions to control and eliminate malaria.","Oswaldo Cruz Foundation|University of Sao Paulo","All","3 Months and older   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DMID 17-0037-A","April 2, 2018","October 31, 2023","July 31, 2024","September 28, 2018",,"September 28, 2018","Marcelo Urbano Ferreira, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03689036"
36,"NCT02532049","A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313",,"Completed","No Results Available","Malaria","Biological: ChAd63 Pfs25-IMX313|Biological: MVA Pfs25-IMX313","Number of Adverse Events|Immunogenicity of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime.|Ex-vivo efficacy of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime. The functional activity of the vaccine induced antibodies will be tested using membrane-feeding assays.","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VAC062","October 12, 2015","May 25, 2017","May 25, 2017","August 25, 2015",,"July 17, 2017","CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02532049"
37,"NCT02511353","Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study","IVERMAL","Completed","No Results Available","Malaria","Drug: ivermectin|Drug: placebo|Drug: dihydroartemisinin-piperaquine","Mosquito survival|Number of patients with malaria clinical and parasitological treatment response|Area under the plasma concentration versus time curve (AUC) of ivermectin|Area under the plasma concentration versus time curve (AUC) of piperaquine|Peak plasma Concentration (Cmax) of ivermectin|Peak plasma Concentration (Cmax) of piperaquine|Tolerability as assessed by adverse events reported in a general toxicity questionnaire|CNS adverse events|Serious adverse events|Haemoglobin concentrations|QTc interval|Mydriasis quantitated by pupillometry","Liverpool School of Tropical Medicine|Kenya Medical Research Institute|Centers for Disease Control and Prevention","All","18 Years to 50 Years   (Adult)","Phase 2","141","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14.002|2775|6720","July 2015","July 2016","July 2016","July 30, 2015",,"August 23, 2018","Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT02511353"
38,"NCT01916954","Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy","ALN5P","Completed","No Results Available","Malaria","Drug: 3-day artemether-lumefantrine|Drug: 5-day artemether-lumefantrine","Pharmacokinetics measures|Tolerability and safety measures","University of Oxford|University of Kinshasa","Female","18 Years to 45 Years   (Adult)","Phase 3","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALN5P","July 2013","March 2014",,"August 6, 2013",,"March 26, 2014","University of Kinshasa, Democratic Republic of Congo, Kinshasa, Congo",,"https://ClinicalTrials.gov/show/NCT01916954"
39,"NCT01540474","Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",,"Completed","No Results Available","Malaria","Biological: Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological: Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE","Safety|AntiFMP-12 antibody titers in serum","U.S. Army Medical Research and Development Command|United States Agency for International Development (USAID)|IDRI","All","18 Years to 50 Years   (Adult)","Phase 1","30","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A-17085|WRAIR 1853","February 2012","October 2012","December 2012","February 28, 2012",,"January 15, 2013","Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01540474"
40,"NCT04230161","Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda",,"Not yet recruiting","No Results Available","Malaria","Other: Standard long-lasting insecticidal net|Other: Chlorfenapyr insecticide treated net|Other: Indoor residual spraying","Cumulative malaria incidence|Vector species composition|Species-specific population densities|Biting behaviors|Estimated entomological inoculation rates|Insecticide resistance profile|Parasite prevalence in children 6 months or older","PATH|Rwanda Biomedical Centre|University of Rwanda|Liverpool School of Tropical Medicine","All","6 Months and older   (Child, Adult, Older Adult)",,"3669","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1409734-2","January 13, 2020","September 1, 2022","December 31, 2022","January 18, 2020",,"January 18, 2020","Rwanda Biomedical Centre, Kigali, Rwanda",,"https://ClinicalTrials.gov/show/NCT04230161"
41,"NCT03503058","Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria",,"Not yet recruiting","No Results Available","Malaria","Biological: PfSPZ Vaccine|Biological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|Other: Normal Saline","The number of adverse events occurring after vaccination and placebo administration|The number of microscopy-confirmed first infections with Pf|The number of microscopy confirmed first infections with Pv in eastern Indonesia|The number of microscopy confirmed first infections with Pv after leaving eastern Indonesia|The number of PCR-confirmed first infections|The immune responses induced by vaccination compared to those induced by placebo administration|Associations between immune responses and protection among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.|Associations between immune responses measured prior to the 24-week period of surveillance beginning after return to Java and the risk of relapse during that period.","Sanaria Inc.|Eijkman Oxford Clinical Research Unit|Indonesia University|Congressionally Directed Medical Research Programs","Male","18 Years to 55 Years   (Adult)","Phase 2","420","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDSPZV1","April 2020","April 2021","June 2021","April 19, 2018",,"January 7, 2020","Department of Internal Medicine, Universitas Indonesia, Jakarta, Indonesia|Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT03503058"
42,"NCT04157894","Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso",,"Recruiting","No Results Available","Malaria","Other: Standard long-lasting insecticidal net|Other: Chlorfenapyr insecticide treated net|Other: Piperonyl butoxide long-lasting insecticidal net","Cumulative malaria incidence|Vector species composition|Species-specific population densities|Biting behaviors|Estimated entomological inoculation rates|Insecticide resistance profile|Parasite prevalence in children 6-59 months","PATH|National Center for Research and Training on Malaria|Liverpool School of Tropical Medicine","All","6 Months and older   (Child, Adult, Older Adult)",,"6734","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1379279-2","July 7, 2019","September 1, 2022","December 31, 2022","November 8, 2019",,"November 8, 2019","Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT04157894"
43,"NCT02533336","The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania","DL","Terminated","No Results Available","Malaria","Drug: abamectin and fenpyroximate","Incidence of malaria parasitemia|Effectiveness of DL on anemia","National Institute for Medical Research, Tanzania|Kilimanjaro Christian Medical Centre, Tanzania|London School of Hygiene and Tropical Medicine|Centers for Disease Control and Prevention|Brandeis University|United States Agency for International Development (USAID)","All","6 Months to 11 Years   (Child)","Phase 3","4917","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DL Project in Tanzania","November 9, 2015","August 31, 2016","March 31, 2017","August 26, 2015",,"February 5, 2019","Muheza, Tanga, Muheza, Tanzania",,"https://ClinicalTrials.gov/show/NCT02533336"
44,"NCT02878265","The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children",,"Completed","No Results Available","Malaria","Dietary Supplement: Vitamin A|Dietary Supplement: Vitamin A and ZInc|Dietary Supplement: Vitamin A , Zinc and Multivitamin","Incidence of clinical malaria attacks|Incidence of diarrhea attacks","University of Ghana|Kwame Nkrumah University of Science and Technology","Female","Child, Adult, Older Adult","Phase 3","547","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VAZ20016","November 2011","May 2012","December 2012","August 25, 2016",,"August 25, 2016","Amoako, Accra, Ghana",,"https://ClinicalTrials.gov/show/NCT02878265"
45,"NCT03568344","Community Access to Rectal Artesunate for Malaria","CARAMAL","Active, not recruiting","No Results Available","Malaria",,"Proportion of children <5 years with severe febrile illness seen by CHW/primary HF that resulted in death within 28 days|Proportion of children <5 years with severe febrile illness without parasites on day 28|Proportion of children <5 years with a recent history of fever (mild or severe) who attend CHW/primary HF|Proportion of children <5 years with severe febrile illness seen by CHW/primary HF who completed referral|Number of children <5 years with severe febrile illness who report directly to referral health facility|Proportion of children <5 years with severe febrile illness managed pre-referral according to guidelines|Proportion of children <5 years with severe febrile illness managed post-referral according to guidelines|Frequency of passively reported adverse events after RAS administration|Frequency of delayed haemolytic anaemia within 28 days after RAS administration|Proportion of trained and functional CHW and primary HF who provide QA RAS|Proportion of CHW/primary HF with RAS in stock|Proportion of referral health facilities that have the capacity to manage severe malaria in children in line with global guidance|Proportion of CHW/primary HF that received at least one supervisory visit in the past 3 months|Acceptability of pre-referral RAS among health workers|Acceptability of pre-referral RAS among caretakers|Total financial cost of managing severe case at community level. Marginal financial cost of adding RAS to the management|Financial cost of RAS interventions per death averted","Swiss Tropical & Public Health Institute|UNITAID|UNICEF|Kinshasa School of Public Health|Akena Associates Ltd.|Clinton Health Access Initiative, USA|Makerere University","All","6 Months to 59 Months   (Child)",,"6032","Other","Observational","Observational Model: Other|Time Perspective: Prospective","P 001-17-1.2","June 15, 2018","May 31, 2020","May 31, 2020","June 26, 2018",,"October 28, 2019","Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the|Akena Associates Ltd., Abuja, Nigeria|Makerere University School of Public Health, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT03568344"
46,"NCT01703884","ANC & Malaria Diagnostic in Pregnancy","AQUAMOD","Completed","No Results Available","Malaria","Drug: ASAQ","Placental malaria at delivery|The proportion of women with peripheral positive malaria infection at delivery","Centre Muraz|World Health Organization","Female","16 Years to 50 Years   (Child, Adult)","Phase 4","5254","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B00531","August 2012","July 2014","December 2014","October 11, 2012",,"July 31, 2015","Dafra & Do districts, Bobo-Dioulasso, Hauts Bassins-houet, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT01703884"
47,"NCT01280162","Malaria Active Epidemiology and Treatment Study",,"Completed","No Results Available","Malaria","Drug: Dihydroartemisinin piperaquine","Comparative efficacy.","Armed Forces Research Institute of Medical Sciences, Thailand|United States Army Medical Materiel Development Activity","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","222","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WRAIR # 1737|HRPO Log Number A-16251","September 2010","February 2011","December 2012","January 20, 2011",,"October 21, 2014","Oddar Meancheay, Oddar Meancheay, Cambodia",,"https://ClinicalTrials.gov/show/NCT01280162"
48,"NCT02601716","PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults",,"Completed","No Results Available","Malaria","Biological: PfSPZ Vaccine|Biological: CHMI (7G8)|Biological: CHMI (NF135.C10)","Incidence and type of Adverse Events|Efficacy|Immunological response|Immunological outcomes","Sanaria Inc.|Naval Medical Research Center|University of Maryland, College Park|Walter Reed Army Institute of Research (WRAIR)|Joint Warfighter Medical Research Program","All","18 Years to 50 Years   (Adult)","Phase 2","92","Industry|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NMRC.2015.0009|CVD Malaria 26000","January 2016","September 2017","November 2017","November 10, 2015",,"October 16, 2018","University of Maryland-Baltimore, Center for Vaccine Development, Baltimore, Maryland, United States|Naval Medical Research Center, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02601716"
49,"NCT01809873","Sustainable Financial Incentives To Improve Prescription Practices For Malaria",,"Completed","No Results Available","Malaria","Behavioral: Performance based incentives","Proportion of children under 5 years of age who are treated with antimalarials following a negative malaria test","Duke University|Moi University","All","Child, Adult, Older Adult","Not Applicable","14862","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research","Pro00035154","September 2012","November 2013","March 2014","March 13, 2013",,"March 10, 2015","Moi University, Eldoret, Rift Valley Province, Kenya",,"https://ClinicalTrials.gov/show/NCT01809873"
50,"NCT02389348","A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265","OZ/DSMCombo","Completed","No Results Available","Malaria","Drug: DSM265|Drug: OZ439","PK/PD relationship on clearance of P falciparum parasites from the blood|Incidence, relation to study drug and severity of AE|Cmax, Tmax, AUC of DSM265 and OZ439","Medicines for Malaria Venture|Q-Pharm Pty Limited|QIMR Berghofer Medical Research Institute|Clinical Network Services (CNS) Pty Ltd","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QP14C12","February 2015","June 2015","June 2015","March 17, 2015",,"October 7, 2015","Q-Pharm Clinics, Herston, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02389348"
51,"NCT03056391","Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria","PACKNOW","Completed","No Results Available","Malaria","Drug: Paracetamol","Effect of Paracetamol on kidney function|Longitudinal change in creatinine|Change in creatinine in severe malaria|Development of AKI|Duration of AKI|Longitudinal changes in haemolysis: plasma cell-free haemoglobin|Longitudinal changes in haemolysis: plasma cell-free haem|Longitudinal changes in haemolysis: haem-to-protein cross-links|Longitudinal changes in markers of oxidative stress: F2-IsoP|Longitudinal changes in markers of oxidative stress: IsoF|Longitudinal changes in F2-IsoPs according to G6PD enzyme activity|Longitudinal changes in IsoFs according to G6PD enzyme activity|Longitudinal changes in CFHb according to G6PD enzyme activity|Longitudinal changes in F2-IsoPs according to G6PD genotype|Longitudinal changes in IsoFs according to G6PD genotype|Longitudinal changes in CFHb according to G6PD genotype|Population pharmacokinetics of paracetamol: Cmax|Population pharmacokinetics of paracetamol: Tmax|Population pharmacokinetics of paracetamol: AUC|Population pharmacodynamics of paracetamol|Fever clearance time|Fever duration|Area above the fever versus time curve (AUC-T°)|Parasite clearance time (hours)|Blood and urine biomarkers of pre-renal and renal injury|Longitudinal urine colour|Longitudinal urine pH|Longitudinal urine specific gravity|Longitudinal urine haemoglobin|Change in creatinine (umol/L) between therapeutic concentrations of paracetamol vs those with absent or low.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Longitudinal red cell deformability|Longitudinal changes in markers of endothelial dysfunction","Menzies School of Health Research","All","5 Years and older   (Child, Adult, Older Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMRR-16-356-29088","October 2016","February 1, 2018","February 1, 2018","February 17, 2017",,"December 19, 2019","Keningau District Hospital, Keningau, Sabah, Malaysia|Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia|Kota Marudu District Hospital, Kota Marudu, Sabah, Malaysia|Ranau District Hospital, Ranau, Sabah, Malaysia",,"https://ClinicalTrials.gov/show/NCT03056391"
52,"NCT03162614","Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",,"Completed","Has Results","Malaria","Biological: RTS,S/AS01E|Biological: RTS,S/AS01B|Procedure: Sporozoite-infected mosquitoes challenge.","Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls|Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule|Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations|Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations|Number of Subjects With Any Solicited Local Symptoms|Number of Subjects With Any Solicited General Symptoms|Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination|Number of Subjects With Any Unsolicited AEs After Challenge|Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination|Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period|Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination|Number of Subjects With Potential Immune Mediated Diseases (pIMDs)|Number of Subjects With Meningitis|Number of Subjects With Abnormal Laboratory Values Gradings|Number of Subjects With Any, Fatal or Related SAE, After Challenge","GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)","All","18 Years to 55 Years   (Adult)","Phase 2","154","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","205081","May 24, 2017","July 9, 2018","September 24, 2018","May 22, 2017","July 24, 2019","November 14, 2019","GSK Investigational Site, Silver Spring, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03162614/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03162614/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03162614"
53,"NCT01018459","Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso",,"Completed","No Results Available","Malaria","Biological: Ad35.CS.01 Circumsporozoite Malaria Vaccine|Drug: Placebo","The number of subjects experiencing severe (Grade 3) solicited injection site reactions.|The number of subjects spontaneously reporting severe (Grade 3) adverse events considered associated with the vaccination.|The number of subjects experiencing severe (Grade 3) solicited systemic reactions|Serious adverse events considered associated with the vaccination reported.|Neutralizing antibody titers against Adenovirus type 35 by Adenovirus Neutralization Assay.|Antibody titers against the malaria circumsporozoite antigen [Geometric Mean Titer and individual log enzyme-linked immunosorbent assay (ELISA) units].","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","08-0037","April 2010","December 2011","December 2011","November 23, 2009",,"June 6, 2014","Centre National de Recherche et de Formation sur le Paludisme - Research and Training, West Africa, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT01018459"
54,"NCT01265407","Malaria Surveillance in Rakai, Uganda",,"Completed","No Results Available","Malaria",,"Episodes of uncomplicated and severe clinical malaria per year in children and adults.|Malaria rates (episodes/per year) in individuals and communities and by seasonality. Clinical episodes will be determined using RDT among febrile participants.|Determine the rates of asymptomatic parasitemia among afebrileparticipants (determined by malaria smears and PCR).|The prevalence of enlarged palpable spleen (splenomegaly) in children","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","6 Months to 99 Years   (Child, Adult, Older Adult)",,"1650","NIH","Observational","Observational Model: Family-Based|Time Perspective: Prospective","999911050|11-I-N050","December 22, 2010",,,"December 23, 2010",,"February 17, 2020","Rakai Health Sciences Program, Rakai, Uganda",,"https://ClinicalTrials.gov/show/NCT01265407"
55,"NCT00384267","Congenital and Neonatal Malaria in Mali",,"Completed","No Results Available","Malaria",,"# of neonates with malaria infection|The rate of acquired malaria|Prevalence of antimalarial antibodies in neonates|The rate of congenital malaria|Prevalence of specific hemoglobin types in study population","National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult",,"44","NIH","Observational","Time Perspective: Prospective","05-0119","October 2006","April 2009","April 2009","October 6, 2006",,"November 11, 2011","Hopital Gabriel Toure, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT00384267"
56,"NCT01054248","Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","DMA","Active, not recruiting","No Results Available","Malaria","Drug: dihydroartemisinin-piperaquine|Drug: Artesunate-mefloquine|Drug: arthemeter-lumefantrin","Cure rate defined as clearance of asexual parasites without recurrence within the period between treatment and delivery or a 63 day period|Number of adverse events|Biochemical and haematological changes|Kinetic parameters of artesunate, mefloquine, piperaquine and lumefantrine|Anaemia|Gametocyte carriage|Changes in the Reticulocyte counts|Malaria infection rate at delivery and placental parasitaemia|Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality)|Infant growth and development at 1 year of life","University of Oxford","All","18 Years to 45 Years   (Adult)","Phase 3","499","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SMRU0905","February 16, 2010","January 2020","January 2020","January 22, 2010",,"October 2, 2018","Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT01054248"
57,"NCT01322581","A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali",,"Recruiting","No Results Available","Malaria",,"Pf expression profiles|serum cytokine profiles|Pf-specific antibody profiles","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","3 Months to 40 Years   (Child, Adult)",,"1600","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","999911126|11-I-N126","May 1, 2011",,,"March 24, 2011",,"February 12, 2020","University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01322581"
58,"NCT01152931","Antioxidant Micronutrients in Malaria","AMM","Completed","No Results Available","Malaria","Drug: Amodiaquine + Artesunate|Drug: Lumefantrine + Artemether|Dietary Supplement: Artesunate + vitamin A|Dietary Supplement: Artesunate + vitamin E|Dietary Supplement: Artesunate + Zinc|Dietary Supplement: Artesunate + selenium|Dietary Supplement: Amodiaquine + vitamin A|Dietary Supplement: Amodiaquine + Vitamin E|Dietary Supplement: Amodiaquine + Zinc|Dietary Supplement: Amodiaquine + Selenium|Dietary Supplement: Artesunate + vitamin A + vitamin E|Dietary Supplement: Artesunate + Vitamin A + Zinc|Dietary Supplement: Artesunate + Vitamin A + Selenium|Dietary Supplement: Artesunate + Vitamin E + Selenium|Dietary Supplement: Artesunate + Vitamin E + Zinc","7-day cure rate|28-day cure rate.","University of Lagos, Nigeria","All","6 Months to 5 Years   (Child)","Phase 3","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ULagosclinicaltrials|ULCT123456|HCC8/T2A/443111","August 2010","November 2010","December 2010","June 29, 2010",,"May 31, 2012","Central Primary Health Centre, Ukpenu, Road, Ekpoma., Ekpoma, Edo State, Nigeria|Faithdome Medical Centre, Ekpoma., Ekpoma, Esan West, Edo State, Nigeria",,"https://ClinicalTrials.gov/show/NCT01152931"
59,"NCT03496454","Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model","CHMI-Gambia1","Completed","No Results Available","Malaria","Other: PfSPZ Challenge","frequency and magnitude of adverse events|time to first detection of parasites and parasites density|Time to Pf-NF54 parasitemia|parasite growth|differences in immune responses","London School of Hygiene and Tropical Medicine|Radboud University|Sanaria Inc.","Male","18 Years to 35 Years   (Adult)","Not Applicable","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SCC 1529","March 29, 2018","May 3, 2018","December 5, 2018","April 12, 2018",,"January 16, 2019","MRC Unit, Fajara, Gambia",,"https://ClinicalTrials.gov/show/NCT03496454"
60,"NCT03960632","Performance Evaluation of Malaria Plus RDTs",,"Not yet recruiting","No Results Available","Malaria","Diagnostic Test: Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))","Estimates of clinical performance characteristics of Pf Plus|Estimates of clinical performance characteristics of Pf/Pv Plus","Foundation for Innovative New Diagnostics, Switzerland","All","5 Years and older   (Child, Adult, Older Adult)",,"6546","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","7874-2/1","July 2019","September 2020","September 2020","May 23, 2019",,"May 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03960632"
61,"NCT01524341","Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",,"Completed","No Results Available","Malaria","Drug: KAE609","Parasite clearance time|Number of participants with adverse events|Area under the curve (AUC)0-24h on Day 1 and Day 3|The accumulation ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1)|Maximum concentration (Cmax) on Day 1 and Day 3|Time to maximum concentration (Tmax) on Day 1 and Day 3|Half-life (T1/2)|Clearance (CL/F )|The apparent volume of distribution during the terminal elimination phase following extravascular administration (Vz/F)","Novartis Pharmaceuticals|Novartis","All","20 Years to 60 Years   (Adult)","Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CKAE609X2201","January 2012","June 2012","June 2012","February 1, 2012",,"May 13, 2013","Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Tak Province, Thailand|Novartis Investigative Site, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT01524341"
62,"NCT02119312","Malaria Clinical Trials Center General Screening","GS","Recruiting","No Results Available","Malaria",,"Participant Enrollment","Fred Hutchinson Cancer Research Center","All","18 Years to 50 Years   (Adult)",,"3500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","MC-002","June 2010","December 2025","December 2025","April 21, 2014",,"October 15, 2019","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02119312"
63,"NCT03483571","Dynamics of Subclinical Malaria: Preliminary Study",,"Recruiting","No Results Available","Malaria",,"Proportion of individuals with initially positive usPCR tests that were followed by 1 or more consecutive positive tests on weekly or biweekly testing|Proportion of individuals with initially negative usPCR tests that subsequently had at least one usPCR positive test at a second screening 4 weeks later|Incidence of falciparum malaria infection by RDT|Incidence of vivax malaria infection by RDT|Incidence of mixed falciparum/vivax malaria infection by RDT|Incidence of falciparum malaria infection by usPCR|Incidence of vivax malaria infection by usPCR|Incidence of mixed falciparum/vivax malaria infection by usPCR|Seroreactivity to polymorphic malaria/mosquito proteins","Duke University|Department of Medical Research, Myanmar Ministry of Health|International Centre for Diarrhoeal Disease Research, Bangladesh|National Institute of Parasitic Diseases, China CDC|Defence Services Medical Research Center, Myanmar","All","6 Months and older   (Child, Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00091895","July 26, 2018","March 2021","October 2021","March 30, 2018",,"December 20, 2019","Department of Medical Research, Yangon, Myanmar","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03483571/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03483571/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03483571"
64,"NCT02329301","Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia",,"Active, not recruiting","No Results Available","Malaria|Malaria, Falciparum","Drug: MDA with DHAp (Eurartesim)|Drug: Focal MDA with DHAp (Eurartesim)","Parasite prevalence during the high transmission season among children <6 years old (excluding neonates <1 month)|P.falciparum infection incidence rate among individuals ≥3 months|Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages|Malaria rapid diagnostic test test positivity rate from focal mass drug administration (fMDA) and mass drug administration (MDA) interventions (plus control group)","PATH|Ministry of Health, Zambia|Minister of Community Development, Mother and Child Health, Zambia|Tulane University","All","3 Months and older   (Child, Adult, Older Adult)","Not Applicable","2430","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PATH-WIRB-20140824","September 2014","June 2016","December 2019","December 31, 2014",,"March 20, 2019","Southern province medical office, Choma, Southern, Zambia",,"https://ClinicalTrials.gov/show/NCT02329301"
65,"NCT01464125","Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults","JP011","Unknown status","No Results Available","Malaria","Drug: Fosmidomycin|Drug: Azithromycin","day 28 cure rate of >95%|Safety and Tolerance|Day 7 cure rate of 100%|Blood samples at 0,1,2,3,4,6,8,12,14,18,24, 26,30,36,38,42,48,50,54,60,62,66,72,78,84,90,96,108,120,144.168.240 hours|PCR corrected cure rates","Jomaa Pharma GmbH|Mahidol University|Thammasat University","All","15 Years to 55 Years   (Child, Adult)","Phase 2","43","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JP011","November 2008","October 2009","December 2011","November 3, 2011",,"November 3, 2011","Mahidol University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01464125"
66,"NCT02251704","Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa",,"Recruiting","No Results Available","Malaria","Procedure: Blood sampling|Diagnostic Test: Assessment of body temperature","Number of subjects infected with P. falciparum parasitaemia (using microscopy)|Number of subjects using malaria control interventions|Number of subjects by demography and medical history characteristics|Number of subjects infected with Plasmodium species other than P. falciparum (using microscopy)|Number of subjects with uptake and timing of the third dose of DTP/HepB/Hib pentavalent and the first dose of the measles EPI vaccines|Number of subjects using anti-malarial therapy in the 14 days prior to the visit|Number of subjects with measured fever at the visit|Number of subjects with reported fever in the 24 hours prior to the visit|Number of subjects demonstrating care seeking behaviour|Number of subjects in each geo-referenced segment|Number of subjects experiencing risk factors","GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)","All","6 Months to 9 Years   (Child)","Not Applicable","54600","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","116682","October 22, 2014","June 15, 2024","June 15, 2024","September 29, 2014",,"January 27, 2020","GSK Investigational Site, Nouna, Burkina Faso|GSK Investigational Site, Ouagadougou, Burkina Faso|GSK Investigational Site, Kintampo, Ghana|GSK Investigational Site, Navrongo, Ghana|GSK Investigational Site, Kisumu, Kenya|GSK Investigational Site, Kisumu, Kenya|GSK Investigational Site, Blantyre 3, Malawi|GSK Investigational Site, Mangochi, Malawi|GSK Investigational Site, Dakar, Senegal|GSK Investigational Site, Tanga, Tanzania",,"https://ClinicalTrials.gov/show/NCT02251704"
67,"NCT03963869","Effectiveness of Malaria Camps as Part of the Odisha State Malaria Elimination Drive","CSCMi20","Recruiting","No Results Available","Malaria","Other: Malaria Camps","Parasite presence|Parasite species|Malaria as detected by RDT|Gametocyte density|Hemoglobin|BMI|Body temperature|Mid-upper arm circumference|Plasmodium-specific serology|Plasmodium parasite genomic epidemiology","NYU Langone Health|Community Welfare Society Hospital|Martin Luther Christian University|Indian Institute of Public Health, India|National Institute of Research in Tribal Health|National Vector Borne Disease Control Programme|University Hospital, Umeå|National Institute of Allergy and Infectious Diseases (NIAID)|New York University","All","1 Year to 69 Years   (Child, Adult, Older Adult)","Not Applicable","2700","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","19-00122","August 3, 2019","September 2020","September 2021","May 28, 2019",,"December 5, 2019","Community Welfare Society Hospital, Rourkela, Odisha, India",,"https://ClinicalTrials.gov/show/NCT03963869"
68,"NCT01921413","Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)",,"Completed","No Results Available","Malaria","Device: Urine Malaria Test","Accuracy of the UMT for Clinical Malaria Diagnosis|Monitoring the Effectiveness of Malaria Treatment by Rapid Urine Testing","Fyodor Biotechnologies Inc|University of Lagos, Nigeria|Johns Hopkins University|Federal Ministry of Health, Nigeria|Duke University","All","2 Years and older   (Child, Adult, Older Adult)",,"1893","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","UMT Evaluation","July 2013","February 2014","February 2014","August 13, 2013",,"April 22, 2014","College of Medicine of the University of Lagos, Idi-Araba, Lagos, Nigeria",,"https://ClinicalTrials.gov/show/NCT01921413"
69,"NCT00563914","A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria",,"Completed","No Results Available","Malaria","Drug: ferroquine (SSR97193)|Drug: amodiaquine","Hepatic safety :ALT, AST, Alkaline Phosphatase, Total Bilirubin|Parasite clearance assessed by repeated measurements of parasitemia|Pharmacokinetics of ferroquine assessed by repeated measurement of blood concentration","Sanofi","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT10420|SSR97193","October 2007","November 2008","November 2008","November 26, 2007",,"December 21, 2009","Sanofi-Aventis Administrative Office, Lambaréné, Gabon|Sanofi-Aventis Administrative Office, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT00563914"
70,"NCT04241705","Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia",,"Not yet recruiting","No Results Available","Malaria","Other: Treatment of positive individuals per national treatment guidelines|Other: Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|Other: Optimized malaria control interventions","Change in malaria annual parasite incidence (API)|Malaria burden, measured by antigen test|Malaria burden, measured by serology|Malaria burden, measured by molecular testing|Intervention coverage|Acceptability|Serious adverse events|Adherence|Costs|Cost-effectiveness|Sensitivity and specificity of polymerase chain reaction (PCR)|Ratio of imported to locally acquired incident cases","Armauer Hansen Research Institute, Ethiopia|Addis Continental Institute of Public Health|U.S. President's Malaria Initiative|U.S. Centers for Disease Control and Prevention|United States Agency for International Development (USAID)|Ethiopian Federal Ministry of Health|Oromia Regional Health Bureau|Tulane University","All","6 Months and older   (Child, Adult, Older Adult)","Not Applicable","48960","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1","January 20, 2020","January 20, 2022","January 20, 2022","January 27, 2020",,"January 28, 2020",,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04241705/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04241705"
71,"NCT01449045","Trial of Malaria Seasonal IPTc Combined With Community Case Management",,"Completed","No Results Available","Malaria","Drug: IPTc+CCM|Drug: Community Case Management with artemether-lumefantrine (AL)","Number of children under 10 years of age with clinical malaria|Number of children under 10 years of age presenting clinical Malaria with high parasite density","Cheikh Anta Diop University, Senegal|London School of Hygiene and Tropical Medicine","All","3 Months to 10 Years   (Child)","Phase 3","4554","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SEN11.16|TA.2010.40200.032","July 2011","December 2011","February 2012","October 7, 2011",,"April 26, 2012","University Cheikh Anta Diop, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT01449045"
72,"NCT00890760","A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites",,"Completed","No Results Available","Malaria","Biological: AdCh63 ME-TRAP|Biological: MVA ME-TRAP|Other: Sporozoite challenge|Biological: Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly","Vaccine prevention (partial or complete) of malaria infection by sporozoite challenge|Safety of vaccine","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MAL 034","March 2009","February 2010","February 2011","April 30, 2009",,"November 29, 2012","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Headington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00890760"
73,"NCT02938975","Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents for Malaria Prevention","URCT","Unknown status","No Results Available","Malaria","Other: Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|Other: Permethrin Factory-Treated Army Combat Uniforms|Other: Placebo lotion|Other: Army combat uniform","Incidence of Plasmodium falciparum malaria through monthly measurement of malaria positivity by direct polymerase chain reaction (PCR) to detect parasite DNA|Incidence of clinical malaria through monthly measurement malaria positivity of SD Bioline Malaria Rapid Diagnostic Test to test for parasite antigen|Compliance with intervention as measured through spot checking and weighing of repellent bottles|Protective efficacy of uniforms measured by reduction in Anopheles arabiensis bites among those wearing uniforms for a sub-sample of uniforms tested under laboratory conditions with free flying mosquitoes","Ifakara Health Institute|Swiss Tropical & Public Health Institute|Walter Reed Army Institute of Research (WRAIR)|U.S. Army Medical Research and Development Command","All","18 Years to 40 Years   (Adult)","Phase 3","1500","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BIT014 PR001 V01","November 2017","January 2019","June 2019","October 19, 2016",,"June 6, 2017","Ifakara Health Institute, Bagamoyo, Tanzania",,"https://ClinicalTrials.gov/show/NCT02938975"
74,"NCT00336388","Use of Rapid Diagnostic Tests for Malaria Case Management in Kenya",,"Completed","No Results Available","Malaria","Device: Paracheck Device","Sensitivity and specificity of malaria diagnosis 6 weeks after the introduction of malaria rapid diagnostic tests|Adherence to malaria case management guidelines by health care workers|Cost effectiveness of malaria case management guidelines using malaria rapid diagnostic tests|Acceptability of malaria rapid diagnostic tests to health care workers|Acceptability of malaria rapid diagnostic tests to patients","Centers for Disease Control and Prevention|Kenya Medical Research Institute|Kenya Division of Malaria Control|KEMRI-Wellcome Trust Collaborative Research Program","All","5 Years and older   (Child, Adult, Older Adult)","Not Applicable","3600","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CDC-NCID-4701","July 2006","September 2006","September 2006","June 13, 2006",,"March 9, 2010","Bondo and Kericho District Health Facilities, Kisumu, Nyanza Province, Kenya",,"https://ClinicalTrials.gov/show/NCT00336388"
75,"NCT00870987","Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria","DNA-Ad","Completed","No Results Available","Malaria","Biological: DNA vaccine prime|Biological: adenovirus type 5 vaccine boost","Number of adverse events|Number of sterile or partial protections|Number of humoral immunity expressions|Number of cellular immunity expressions","U.S. Army Medical Research and Development Command|United States Agency for International Development (USAID)|Walter Reed Army Institute of Research (WRAIR)","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","82","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","WRAIR 1550|HRPO #A-15350|NMRC.2009.0004","May 2009","April 2014","July 2015","March 30, 2009",,"September 23, 2019","Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00870987"
76,"NCT02163447","Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants","PROMOTE-BC1","Completed","Has Results","Malaria","Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants|Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants","Prevalence of Placental Malaria|Incidence of Malaria in Pregnant Women|Incidence of Malaria in Infants|Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP|Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery|Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery|Prevalence of Anemia in Pregnant Women|Incidence of Complicated Malaria in Infants|Incidence of Hospital Admissions in Infants|Prevalence of Gametocytemia in Pregnant Women and Infants|Prevalence of Parasitemia in Infants|Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROMOTE-BC1|P01HD059454","June 23, 2014","May 14, 2018","May 14, 2018","June 13, 2014","November 14, 2018","November 15, 2018","IDRC Research Clinic -Tororo District Hospital, Tororo, Uganda","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02163447"
77,"NCT03276962","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age",,"Active, not recruiting","No Results Available","Malaria","Biological: RTS,S/AS01E (Full dose)|Biological: RTS,S/AS01E (1/5th dose)|Biological: Rabies vaccine","The occurrence of clinical malaria meeting the primary case definition.|The occurrence of clinical malaria meeting the primary and secondary case definitions.|The occurrence of incident P. falciparum infections.|The prevalence of P. falciparum infections defined by positive blood slide at each cross-sectional survey.|Number of seropositive subjects for anti-CS antibodies (in a sub-cohort of first 25 subjects enrolled in each group per site).|Number of seropositive subjects for anti-HBs antibodies (in a sub-cohort of first 25 subjects enrolled in each group per site.|Antibody concentrations for anti-CS (in a sub-cohort of first 25 subjects enrolled in each group per site).|Antibody concentrations for anti-HBs. (in a sub-cohort of first 25 subjects enrolled in each group per site).|Number of subjects with any, fatal and related SAEs.|Number of subjects with any AE and SAE leading to withdrawal from further vaccination.|Number of subjects with severe malaria and cerebral malaria.|Number of subjects with potential Immune mediated diseases (pIMDs).|Number of subjects with meningitis.|Number of subjects with of seizures.|Number of subjects with generalized convulsive seizures.|Number of subjects with any unsolicited AE(s).|Number of subjects with abnormal laboratory values. (in a sub-cohort of first 25 subjects enrolled in each group per site).|Number of subjects with any solicited local and general symptoms. (in the reactogenity sub-cohort of first 25 subjects enrolled per site)","GlaxoSmithKline","All","5 Months to 17 Months   (Child)","Phase 2","1500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","204889|2016-000290-20","September 28, 2017","July 16, 2020","December 15, 2022","September 8, 2017",,"May 29, 2019","GSK Investigational Site, Kumasi, Ghana|GSK Investigational Site, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT03276962"
78,"NCT03512678","Evaluation of a Digital Microscope for Malaria","EasyScan Go","Recruiting","No Results Available","Malaria",,"Diagnostic sensitivity for malaria parasite detection|Diagnostic specificity for malaria parasite detection|Kappa statistic for parasite species identification|Bland-Altman plots for parasite density estimation|Reliability (comparison between 2 devices and repeat reads)|Cost-effectiveness as compared with routine methods|Prevalence of parasite genetic markers of resistance to antimalarials by location and time period|Prevalence of parasites carrying deletions of pfhrp2/3 genes by location and time period","University of Oxford","All","6 Months to 75 Years   (Child, Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAL18002","June 25, 2018","December 2019","December 2019","May 1, 2018",,"September 17, 2019","Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand",,"https://ClinicalTrials.gov/show/NCT03512678"
79,"NCT02739763","Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)","CHMI-SIKA","Recruiting","No Results Available","Malaria","Biological: Plasmodium falciparum sporozoite (PfSPZ)","Infectivity of PfSPZ (malaria infection) as determined by quantitative PCR|Safety profile of PfSPZ challenge via direct venous injection|Parasite growth rates with respect to antibody responses to over 100 falciparum antigens","University of Oxford|KEMRI-Wellcome Trust Collaborative Research Program|Sanaria Inc.|KEMRI Centre for Clinical Research|Pwani University|University of Cambridge|Wellcome Trust Sanger Institute","All","18 Years to 45 Years   (Adult)","Phase 1","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OXTREC 2-16|KEMRI/CGMRC/CSC/029/2015","May 2016","January 2020","November 2020","April 15, 2016",,"May 30, 2016","KEMRI Wellcome Trust Research Programme, Kilifi, Coast, Kenya|KEMRI Centre for Clinical Research, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT02739763"
80,"NCT02471378","Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates",,"Recruiting","No Results Available","Malaria",,"Measure of functional activity of animal IgG against vaccine candidates to block binding of fresh pregnancy malaria isolates to the placental receptor CSA|Measurement of parasite density in the in-vitro binding inhibition assay","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Female","15 Years to 25 Years   (Child, Adult)",,"4791","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","999915147|15-I-N147","July 26, 2015","June 30, 2021","June 30, 2021","June 15, 2015",,"April 10, 2019","Malaria Research and Training Center, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT02471378"
81,"NCT04041973","Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)","PAL_Cambodia","Not yet recruiting","No Results Available","Malaria","Drug: Artemether-lumefantrine|Dietary Supplement: Multivitamin","28-day PCR positivity rate of Plasmodium infections of any species.|Proportion of participants with confirmed clinical malaria of any species reported between day 0 and day 28|28-day, 56-day, and 84-day PCR Plasmodium positivity rate for each species|Proportion of participants with confirmed malaria reported between day 0 and day 28 for each species|Incidence of confirmed clinical malaria cases as reported to government health facilities and village malaria workers.surveillance data.|Prevalence of Kelch13 mutations and other genetic markers of antimalarial drug resistance of known functional significance.|Incidence of adverse events and serious adverse events by study arms during the course of prophylaxis.|a. Number of people living in each village b. Number of people working in each reported location c. Number of people who have travelled to different locations within the preceding 2 months d. Number of people who have a mobile phone for their own use|Latitude and longitude of the study participant over time in decimal degrees as recorded every 10-30 minutes by a GPS logging device.|Overall prevalence of Plasmodium at baseline, stratified by season and risk factors.|Day 0, 28, 56 and 84 capillary blood levels of lumefantrine.|Prevalence of serological diagnostic markers of other infectious diseases.","University of Oxford|Global Fund","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","4400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","MAL19001","July 2019","July 2020","December 2020","August 1, 2019",,"August 1, 2019",,,"https://ClinicalTrials.gov/show/NCT04041973"
82,"NCT01228344","Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria",,"Completed","No Results Available","Malaria","Other: Artemether-lumefantrine","Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start|Adverse event, serious adverse event after artemether-lumefantrine treatment start|Pregnancies after artemether-lumefantrine treatment start","Novartis Pharmaceuticals|Centers for Disease Control and Prevention|Novartis","All","Child, Adult, Older Adult",,"324","Industry|U.S. Fed","Observational","Observational Model: Other|Time Perspective: Other","CCOA566A2424","May 1, 2010","September 30, 2015","September 30, 2015","October 26, 2010",,"April 7, 2017","Centers for Disease Control and Prevention,GA, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01228344"
83,"NCT00944840","Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia",,"Completed","No Results Available","Malaria","Drug: SP plus amodiaquine|Drug: SP placebo plus amodiaquine placebo","Malaria incidence (the number of study subjects seen at the OPD clinic with clinical malaria during the surveillance period).|prevalence of parasitaemia at the end of malaria transmission season in December 2008","London School of Hygiene and Tropical Medicine","All","3 Months to 59 Months   (Child)","Phase 3","1312","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SCC 1124","September 2008","July 2009","August 2009","July 23, 2009",,"January 26, 2017","Farafenni Field Station, MRC Laboratories, Farafenni, North Bank Region, Gambia",,"https://ClinicalTrials.gov/show/NCT00944840"
84,"NCT03304704","Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali",,"Recruiting","No Results Available","Malaria",,"Measurement of estimated rates of Infection rate in mosquitoes by DSF measured as the rate (per blood-fed mosquito) of malaria transmission (human to mosquito)","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","6 Months to 65 Years   (Child, Adult, Older Adult)",,"4800","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999917180|17-I-N180","January 27, 2018","December 31, 2020","December 31, 2020","October 9, 2017",,"December 20, 2019","Bancoumana Malaria Vaccine Center, Bamako, Mali|Doneguebougou Facility, Doneguebougou, Mali",,"https://ClinicalTrials.gov/show/NCT03304704"
85,"NCT00984763","A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria",,"Completed","No Results Available","Malaria","Biological: AMA1-C1/Alhydrogel® + CPG 7909","To demonstrate a correlation between in vitro growth inhibition assay and parasite multiplication rate in vivo|To detect differences in the multiplication rate responses between unvaccinated control subjects and volunteers vaccinated with AMA1-C1/Alhydrogel® + CPG 7909","University of Oxford|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","8","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VAC035","January 2010","September 2010","September 2010","September 25, 2009",,"May 28, 2015","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Headington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00984763"
86,"NCT02504918","Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children",,"Completed","No Results Available","Malaria",,"To investigate the association of recent malaria infection and percentage of PD1+ CD4 T cells in children that have not received SMC during the rainy season.|To compare the percentage of PD1 +CD4 T cells in children who do or do not receive antimalarial treatment, in both rainy season and drythedry season.|To compare and describe levels of regulatory T cells in children who do or do not receive antimalarial treatment, in both rainy season and dry season. To compare and describe T cell stimulation responses in children who do or do not receive anti...|To determine and investigate phenotypic differences in T cell subsets in infected and uninfected subjects at baseline.|To confirm that blood stage parasite burden is markedly reduced throughout the dry season by a single treatment with artemether-lumefantrine at enrollment; and to examine the association of parasite clearance during the dry season on malaria ris...","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","12 Months to 59 Months   (Child)",,"200","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999915163|15-I-N163","July 21, 2015","December 31, 2016","June 12, 2018","July 22, 2015",,"June 14, 2018","Ouelessebougou Clinical Research Center MRTC/ FMPOS, Ouelessebougou, Mali",,"https://ClinicalTrials.gov/show/NCT02504918"
87,"NCT03281291","An Ancillary Study Protocol to GSK's Phase IIb Malaria Vaccine Trial Entitled ""Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age""",,"Active, not recruiting","No Results Available","Malaria",,"Time to the first new malaria infection.|Number of new malaria infections during a specified follow-up period.","GlaxoSmithKline","All","5 Months to 17 Months   (Child)",,"1500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","206213","September 28, 2017","June 21, 2021","June 21, 2021","September 13, 2017",,"June 3, 2019","GSK Investigational Site, Kumasi, Ghana|GSK Investigational Site, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT03281291"
88,"NCT01456858","Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies",,"Completed","No Results Available","Malaria","Other: Insecticide Treated Polyethylene Sheeting|Other: Untreated Plastic Sheeting","Malaria Incidence|Anaemia (From Haemoglobin levels)|Adverse Event to ITPS","The Mentor Initiative|ECHO|UNHCR Country Office Freetown|World Health Organization|Wageningen University|London School of Hygiene and Tropical Medicine|National Malaria Control Programme Sierra Leone|Institut de Recherche pour le Developpement","All","4 Months to 36 Months   (Child)","Phase 3","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","TPS_210_202_01033/01034/01035","December 2003","July 2004","July 2004","October 21, 2011",,"October 21, 2011","The Mentor Initiative, Freetown, Sierra Leone",,"https://ClinicalTrials.gov/show/NCT01456858"
89,"NCT01976325","Evaluating the Ottawa Malaria Decision Aid","OMDA","Unknown status","No Results Available","Malaria","Other: Ottawa Malaria Decision Aid","Travellers' Knowledge Score|Decisional Conflict Score|Preparation for Decision-making Score|Medication Adherence Score","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2010462-01H","January 2014","November 2015","November 2015","November 5, 2013",,"April 16, 2015","National Capital Region Occupational Health Clinic, Ottawa, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|International Association for Medical Assistance to Travellers, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01976325"
90,"NCT03432039","Preventing Mental Health Problems After Childhood Severe Malaria",,"Unknown status","No Results Available","Malaria","Behavioral: Psychoeducation|Behavioral: Behavioral","Presence of a behavioral problem|Maternal anxiety and depression|Behavioral problems in the child","Makerere University","All","18 Months to 4 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","REC 2017-088","January 9, 2018","November 30, 2018","November 30, 2018","February 13, 2018",,"February 13, 2018","Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT03432039"
91,"NCT00863408","Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali",,"Completed","No Results Available","Malaria",,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 65 Years   (Adult, Older Adult)",,,"NIH","Observational","Time Perspective: Prospective","999909093|09-I-N093","March 3, 2009",,"March 10, 2010","March 18, 2009",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00863408"
92,"NCT01255215","Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial",,"Completed","No Results Available","Severe Malaria","Drug: Inhaled Nitric Oxide","Change in serum angiopoietin-2 level|Mortality|Time to hospital discharge|Time to parasite clearance.|Biomarkers and genetic determinants of endothelial activation, inflammation and coagulopathy, to be determined.","University Health Network, Toronto|Makerere University|University of Toronto","All","1 Year to 10 Years   (Child)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","iNO RCT","July 2011","July 2013","January 2014","December 7, 2010",,"February 20, 2014","Jinja Regional Referral Hospital, Jinja, Uganda",,"https://ClinicalTrials.gov/show/NCT01255215"
93,"NCT02974608","Impact of Malaria on Pregnant Women in Ouelessebougou, Mali",,"Recruiting","No Results Available","Malaria",,"Assess the rate of fetal loss during the 2nd and 3rd trimesters|Prevalence of malaria infection|Assess the prevalence rate of SP resistant parasites|Assess the rate of pre-term and low birth weight deliveries","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"11000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","999917018|17-I-N018","February 15, 2017","January 31, 2021","January 31, 2021","November 28, 2016",,"September 20, 2019","Ouelessebougou Clinical Research Center (Malaria Research and Training Center), Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT02974608"
94,"NCT04245033","Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in Tanzania","IPTsc","Not yet recruiting","No Results Available","Malaria","Drug: Dihydroartemisinin-Piperaquine (DP)","Efficiency of school health teachers to deliver antimalarial drugs to school children in high endemic regions|Clinical malaria incidence|Change in malaria incidence per 1000 population at local health facility level|Change from baseline in haemoglobin concentration|Number of participants with treatment-related adverse events|Cardio safety profile by QTc prolongation from baseline|Acceptability of IPTsc in communities with high malaria endemicities","National Institute for Medical Research, Tanzania|National Malaria Control Program, Tanzania","All","5 Years to 15 Years   (Child)","Phase 4","4032","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IPTsc version 1","February 10, 2020","January 31, 2021","February 28, 2021","January 28, 2020",,"January 28, 2020","Handeni Town Council, Handeni and Kilindi Districts, Tanga, Tanzania",,"https://ClinicalTrials.gov/show/NCT04245033"
95,"NCT01907672","The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level","GhanaCommRDT","Completed","No Results Available","Malaria","Procedure: Rapid Diagnostic Test","The proportion of clients negative for malaria by double read research blood slide who received an anti-malarial in both arms|Proportion of mRDT -ve clients who received an anti-malarial in the RDT arm|Proportion of clients tested using a Rapid Diagnostic Test|Proportion of clients in each arm receiving an antibiotic|Proportion of clients receiving addittional or alternative treatments to antimalarial and which these are","Ghana Health Services|London School of Hygiene and Tropical Medicine","All","6 Months and older   (Child, Adult, Older Adult)","Phase 4","4748","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ITDCVT68|MCDC_SF_02","August 2011","December 2012","April 2013","July 25, 2013",,"July 25, 2013","Dodowa Health Research Centre, Ghana Health Service, Dodowa, Greater Accra, Ghana",,"https://ClinicalTrials.gov/show/NCT01907672"
96,"NCT01641289","Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria",,"Completed","No Results Available","Malaria","Drug: Paracetamol|Drug: No Paracetamol","Effect of paracetamol concentrations|Compare treatment arm with control arm with respect to duration of Acute Kidney Injury (AKI) and development of AKI.|Compare between groups correlations between oxidative stress, cell-free hemoglobin and renal function|Assessment of Blackwater fever and association with renal function|Mortality and hemodialysis trends|Host factors of Intravascular Haemolysis|Fever clearance time|Parasite clearance time|Parasite sequestration|Assessment of Acute Kidney Injury|Urine scoring of dehydration and haemolysis|Safety assessment|Assess the antimalarial drug sensitivity of patients treated with paracetamol|Paracetamol pharmacokinetics|Paracetamol pharmacodynamics|Area under the plasma concentration versus time curve (AUC)|The maximum concentration (Cmax)","University of Oxford","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BAKMAL1201","July 10, 2012","September 13, 2014","September 21, 2014","July 16, 2012",,"June 14, 2018","Chittagong Medical College Hospital, Chittagong, Bangladesh|Ramu Upazilla Health Complex, Ramu, Bangladesh",,"https://ClinicalTrials.gov/show/NCT01641289"
97,"NCT01743417","Computerized Cognitive Rehabilitation in Children After Severe Malaria","CM_CCRT","Completed","No Results Available","Malaria","Behavioral: Computerised cognitive rehabilitation training","Executive attention|Working memory","Makerere University|Michigan State University|University of Michigan","All","5 Years to 12 Years   (Child)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1R01HD064416-01A1","April 2011","August 23, 2016","August 23, 2016","December 6, 2012",,"May 22, 2017","Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT01743417"
98,"NCT01575613","Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission","REDHOT","Completed","No Results Available","Malaria","Drug: Artemether-lumefantrine combination|Biological: Bacillus thuringiensis|Biological: Long lasting insecticide treated net (LLINs)|Biological: Indoor Residual Spraying (IRS)","Parasite prevalence in the evaluation zone surrounding malaria hotspots|Parasite prevalence inside malaria hotspots|Parasite prevalence in the evaluation zone as function of distance to the hotspot boundary|Anopheles mosquito density|Passive case detection|Safety and acceptability of interventions|Mosquito breeding site productivity","Radboud University|London School of Hygiene & Tropical Medicine, London, UK|Kenya Medical Research Institute|Centers for Disease Control and Prevention|International Centre of Insect Physiology and Ecology (ICIPE)|Division of Malaria Control, Ministry of Health, Nairobi, Kenya","All","6 Months and older   (Child, Adult, Older Adult)","Not Applicable","17506","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","REDHOT_OPP1024438","April 2012","November 2012","November 2012","April 11, 2012",,"November 27, 2012","Rachuonyo District, Kenya",,"https://ClinicalTrials.gov/show/NCT01575613"
99,"NCT03576313","Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","MASSIV","Recruiting","No Results Available","Malaria","Drug: dihydroartemisinin-piperaquine (DP)|Drug: ivermectin (IVM)|Other: standard malaria control interventions only","prevalence of malaria infection|Vector's parous rate|malaria prevalence|incidence of clinical (laboratory confirmed) malaria cases|serological markers of recent malaria|serological markers of recent Anopheles exposure|mosquito density|mosquito mortality|sporozoite rates in field-caught mosquitoes","London School of Hygiene and Tropical Medicine|Institute of Tropical Medicine, Belgium|National Malaria Control Programme, The Gambia|Liverpool School of Tropical Medicine|Radboud University|University of Durham|Imperial College London","All","6 Months and older   (Child, Adult, Older Adult)","Phase 3","6400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SCC 1593","August 11, 2018","August 2020","December 2021","July 3, 2018",,"November 29, 2018","Basse Villages, Basse Santa Su, Gambia",,"https://ClinicalTrials.gov/show/NCT03576313"
100,"NCT02563704","A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon",,"Completed","No Results Available","Malaria","Drug: Artesunate|Drug: Quinine","Fever clearance time|Coma recovery time|Time to sit unsupported|Time to eat and drink|Parasite clearance time|Parasite reduction rate 24 hours after onset of treatment","University of Yaounde 1","All","3 Months to 15 Years   (Child)","Phase 3","238","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UYaounde1","September 2013","March 2014","March 2014","September 30, 2015",,"October 1, 2015",,,"https://ClinicalTrials.gov/show/NCT02563704"
